Notice of Celon Pharma S.A.’s Management Board on repealing the decision on temporary withholding of one Salmex batch (batch no.: 223020018)

Information of the Management Board of Celon Pharma S.A.. The Management Board of Celon Pharma S.A. announced that on 10 August 2018 the Chief Pharmaceutical Inspector repealed its decision No. 4/WS/2018 of 21.06.2018 on the voluntary, temporary withholding of one batch of Salmex, (500 µg + 50 µg), number 223020018. The results of tests conducted onRead more »

Researchers from Celon Pharma S.A.’s R&D Centre publish their article in the prestigious European Journal of Medicinal Chemistry

At the end of May, the prestigious scientific journal European Journal of Medicinal Chemistry published an article of researchers from our R&D Division: Rafał Moszczyński-Petkowski, Jakub Majer, Małgorzata Borkowska, Łukasza Bojarski, Sylwia Janowska, Mikołaj Matłoka, Filip Stefaniak, Damian Smuga, Katarzyna Bazydło, Krzysztof Dubiel and Maciej Wieczorek. The publication’s subject is: Synthesis and characteristics of two newRead more »

Celon Pharma S.A. at the American Diabetes Association’s 78th Scientific Sessions

On 24 June 2018, representatives of Celon Pharma’s Metabolic Disorders Research Group will take part in a poster session, during which they will make a presentation on the following subject: Discovery of CPL207-280ca, an effective and safe GPR40 agonist for the treatment of type 2 diabetes. The conference is the world’s largest event bringing together researchers,Read more »

Salmex registered in another Central American country

Salmex received marketing authorisation on another foreign market – in Honduras – it will be marketed under the name Ventiflu Discus. The marketing authorisation process was intermediated by the Company’s business partner under a commercial agreement. Honduras is another market in Central America, after Guatemala and El Salvador, where the Company has registered its product.Read more »

Maciej Wieczorek is a member of the jury of the Polish President’s Economic Award

President of the Management Board of Celon Pharma S.A. was appointed a member of the jury for the 14th edition of the Polish President’s Economic Award. Maciej Wieczorek joined the interdisciplinary group of experts representing business, science, media, non-governmental organisations and capital market institutions, who will nominate companies for the Polish President’s Economic Award. ThisRead more »

Celon Pharma S.A. at the 2018 BIO International Convention

Between 4 and 7 June this year, representatives of our Company are taking part in the largest global Life Sciences networking meeting. Our participation at this event is one of the elements of our implementing our strategy to increase Celon Pharma’s international presence and our planned global commercialisation of the Company’s innovative portfolio. Bogdan Manowski, DirectorRead more »

Finalised DCP registration procedure for Salmex at the German market

In the German market, Salmex will be available under the trade name Salflutin. After completing the DCP registration procedure, the German drug registration authority will verify the national version of the information materials (including the leaflet, the medicine package) and will issue a final decision on marketing authorisation within the time limits set by theRead more »